GlassScriptPhysician profile
Amanda J Bratton
NPI 1093127607
$2,402.56
in general payments reported to CMS, 2019-2025
26 companies · $2,142 in 2025
The $2,142 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.89 · 2022: $51.21 · 2023: $45.86 · 2024: $121 · 2025: $2,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258 · Education: $51.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,258.08 |
| Education | $51.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $422.08 | 2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $253.68 | 2025 | Trelegy Ellipta, Arexvy, Nucala |
| Verona Pharma, INC. | $218.13 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $181.41 | 2025 | Sunosi |
| Viatris Specialty LLC | $158.68 | 2025 | Yupelri |
| Lilly USA, LLC | $121.18 | 2024 | Mounjaro |
| Regeneron Healthcare Solutions, INC. | $109.64 | 2025 | Dupixent |
| Insmed, INC. | $103.35 | 2025 | Brinsupri, Arikayce |
| Jazz Pharmaceuticals INC. | $98.30 | 2025 | |
| Grifols USA, LLC | $96.42 | 2025 | Prolastin-C Liquid |
| Amgen INC. | $90.62 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $90.04 | 2025 | Glassia |
| Harmony Biosciences LLC | $88.93 | 2025 | |
| Genzyme Corporation | $71.76 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.41 | 2023-2025 | Ofev |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41.89 | 2021 | |
| Novo Nordisk INC | $31.51 | 2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $28.29 | 2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $28.12 | 2025 | Uptravi, Opsumit, Opsynvi |
| Resmed Corp | $17.31 | 2025 | |
| Electromed, INC. | $16.42 | 2025 | Smartvest |
| Inspire Medical Systems, INC. | $16.18 | 2025 | Inspire |
| Mannkind Corporation | $13.99 | 2022 | |
| Abbott Laboratories | $13.13 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.21 | 2022 | |
| Kyowa Kirin, INC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bratton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.